You are here: Industry Insights > neutralizing antibodies

News List

Neutralizing Antibodies, the “Specific Drugs” against SARS-CoV-2 PharmaSources/Yefenghong
March 04, 2021
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed into a global pandemic and become a serious public health and socioeconomic burden, and thus there is an urgent need for effective means of control.
Junshi and Eli Lilly have reached a USD 255 million COVID-19 Virus Antibody Authorization Deal CPhI.CN
May 06, 2020
On May 4, Junshi Biosciences and Eli Lilly Pharma announced that the two parties have reached an agreement to jointly develop and commercialize SARS-CoV-2 neutralizing antibodies against new coronary pneumonia caused by the new SARS-CoV-2 coronavirus.
NewsPoints AstraZeneca has higher efficacy with Medigen: study FirstWordPharma
December 06, 2021
Researchers running a trial in Taiwan, China have found that a combination of AstraZeneca's COVID-19 vaccine and the locally-developed Medigen shot is more effective than two doses of AstraZeneca, reported Taipei Times.
Neutralizing antibodies protect against severe COVID-19 worldpharmanews
December 21, 2020
Understanding the body's immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines.
GenScript Receives EUA for SARS-CoV-2 Neutralizing Antibody Detection Kit americanpharmaceuticalreview
November 18, 2020
GenScript USA announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit.
Ultrapotent COVID-19 vaccine candidate designed via computer worldpharmanews
November 04, 2020
An innovative nanoparticle vaccine candidate for the pandemic coronavirus produces virus-neutralizing antibodies in mice at levels ten-times greater than is seen in people who have recovered from COVID-19 infections.